Charles Schwab Investment Management Inc Crinetics Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 766,228 shares of CRNX stock, worth $32.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
766,228
Previous 753,527
1.69%
Holding current value
$32.8 Million
Previous $25.3 Million
12.81%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding CRNX
# of Institutions
238Shares Held
90.2MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$397 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$274 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$267 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$249 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$240 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.3B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...